Department of adult hematology

A Phase 3 protocol for patients aged 18 to 65 with B-cell, T-cell, or Philadelphia chromosome-positive ALL. The objective of this trial, based on conventional treatment regimens, is to evaluate the early use of immunotherapy during treatment and to better redefine the role of allogeneic stem cell transplantation.

A Phase 1/2 clinical trial evaluating the addition of salazopyrine to standard chemotherapy in patients over 60 with AML, to assess clinical tolerance (Phase 1) and subsequently the impact on the depth of response achieved (Phase 2).

This protocol aims to record patient management under routine care, by collecting a maximum of biological information at all phases of treatment. The goal is to better understand acute leukemias and continue to improve outcomes.

A Phase 3 clinical trial evaluating the addition of a targeted anti-FLT3 therapy to a conventional chemotherapy regimen throughout treatment in patients aged 18 to 70 with AML.

A non-interventional research protocol aiming to understand and dissect the mechanisms of chemotherapy during the first hours and subsequent days of treatment.

Phase 2 Protocol evaluating two intensive chemotherapy modalities—conventional versus encapsulated—in patients over 50 years old with acute myeloid leukemia (AML) of intermediate or unfavorable genetic risk.